SCHEMBL6732153

SCHEMBL6732153

O=C(Oc1ncc(-c2ccncc2)cn1)N1CCN(S(=O)(=O)c2[nH]c3ccc(Cl)cc3c2CO)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
MAPT P10636 1/20 0.36
F10 P00742 2/20 0.36
LSS P48449 2/20 0.35
POLB P06746 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 2/20 0.33
CHUK O15111 1/20 0.33
HTT P42858 1/20 0.33
GAA P10253 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735109 0.91 ALDH1A1 (0.37) ALDH1A1MAPTF10LSSPOLB
SCHEMBL6730820 0.89 ALDH1A1 (0.38) ALDH1A1MAPTF10LSSPOLB
SCHEMBL6728488 0.87 ALDH1A1 (0.38) ALDH1A1MAPTF10POLBKMT2A
SCHEMBL6725420 0.86 ALDH1A1 (0.38) ALDH1A1MAPTF10LSSPOLB
SCHEMBL6730822 0.83 LSS (0.48) ALDH1A1F10LSSKMT2AMEN1
SCHEMBL6786248 0.78 F10 (0.44) ALDH1A1F10LSSLMNAL3MBTL1
SCHEMBL6781215 0.77 F10 (0.37) ALDH1A1F10POLBKMT2ASMN1; SMN2
SCHEMBL6729147 0.76 MEN1 (0.42) ALDH1A1MAPTKMT2ASMN1; SMN2NPSR1
SCHEMBL6726115 0.75 F10 (0.50) ALDH1A1F10LSSKMT2AMEN1
SCHEMBL6737705 0.73 ALDH1A1 (0.37) ALDH1A1MAPTF10LSSSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 ALDH1A1 1316/4885MAPT 4665/4885F10 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.